Changes in Melanoma Subpopulations During Immunotherapy
Author Information
Author(s): Willemsen M., Bulgarelli J., Chauhan S.K., Lereim R.R., Angeli D., Grisendi G., Krebbers G., Davidson I., Kyte J.A., Guidoboni M., Luiten R.M., Bakker W.J.
Primary Institution: Amsterdam University Medical Centers, Location AMC, University of Amsterdam, Cancer Center Amsterdam, Amsterdam Institute for Immunology and Infectious Diseases, Amsterdam, The Netherlands
Hypothesis
How do AXL+ and MITF+ melanoma subpopulations change in response to immunotherapy?
Conclusion
MITF+ melanoma cells are effectively targeted by immunotherapy, while AXL+ melanoma cells show resistance.
Supporting Evidence
- MITF+ melanoma cells significantly decreased upon immunotherapy.
- AXL+ melanoma cell numbers remained stable during treatment.
- Changes in AXL+ or MITF+ tumor cells did not correlate with improved survival.
Takeaway
This study looked at different types of melanoma cells and found that some respond well to treatment while others do not.
Methodology
The study used NanoString gene expression analysis, single-cell RNA sequencing, and multiplex immunofluorescence to analyze tumor samples.
Potential Biases
Potential biases may arise from the limited number of patients and the variability in treatment responses.
Limitations
The study had a small sample size, which may limit the generalizability of the findings.
Participant Demographics
Patients included both males and females with varying ages and melanoma mutation statuses.
Statistical Information
P-Value
0.0494
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website